DiaMedica Therapeutics (DMAC) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 41.3% versus a gain of 16.5%. Over five years, DMAC leads with a +94.9% price change compared with -34.4% for OVID. Ovid Therapeutics is the larger company by market cap ($460.9 million vs $430.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | OVID |
|---|---|---|
| Share price | $7.99 | $2.36 |
| Market cap | $430.87M | $460.90M |
| 1-day change | -1.72% | -0.42% |
| YTD return | +0.38% | +44.79% |
| 1-year return | +16.47% | +41.32% |
| 5-year return | +94.88% | -34.44% |
| EPS (TTM) | $-0.72 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.42 | $3.11 |
| 52-week low | $5.25 | $1.18 |
| Distance from 52-week high | -23.32% | -23.99% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.99% | +155.08% |
| Average volume | 175.72K | 1.58M |
| Shares outstanding | 53.93M | 195.30M |
| Employees | 35 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed DMAC by 24.8 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
DMAC vs OVID FAQ
Which is bigger, DiaMedica Therapeutics or Ovid Therapeutics?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $460.90M compared with $430.87M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or OVID?
OVID returned +41.32% over the past 12 months, compared with +16.47% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.